Oncocyte to Participate at Needham Virtual Cancer Diagnostics Conference

Rhea-AI Summary

Oncocyte Corporation (NYSE American: OCX) will engage in 1-on-1 meetings at the Needham Virtual Cancer Diagnostics 1x1 Conference on August 18, 2020. The company specializes in molecular diagnostics aimed at enhancing cancer care. Their launched test, DetermaRx, identifies early-stage lung cancer patients at high risk for recurrence, optimizing treatment through timely adjuvant chemotherapy. Additionally, they are developing DetermaIO, which assesses patient response to immunotherapies. These innovations aim to improve patient outcomes significantly.

IRVINE, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced that company management will participate in the 1-on-1 meetings at the upcoming Needham Virtual Cancer Diagnostics 1x1 Conference on Tuesday, August 18, 2020.

About Oncocyte Corporation

Oncocyte is a molecular diagnostics company whose mission is to provide actionable answers at critical decision points across the cancer care continuum, with the goal of improving patient outcomes by accelerating and optimizing diagnosis and treatment. The Company recently launched DetermaRx™, a treatment stratification test that enables the identification of early-stage lung cancer patients at high risk for recurrence post-resection, allowing them to be treated when their cancer may be more responsive to adjuvant chemotherapy. Oncocyte is also developing DetermaIO™, a gene expression test that identifies patients more likely to respond to checkpoint immunotherapies.

DetermaRx and DetermaIO are trademarks of Oncocyte Corporation.

Investor Contact
Bob Yedid
LifeSci Advisors, LLC
646-597-6989
bob@lifesciadvisors.com

Media Contact
Cait Williamson, Ph.D.
LifeSci Communications, LLC
646-751-4366
cait@lifescicomms.com

Source: Oncocyte Corporation

FAQ

What is Oncocyte Corporation's mission?

Oncocyte Corporation aims to provide actionable answers at critical decision points across the cancer care continuum to improve patient outcomes.

When will Oncocyte Corporation participate in the Needham Conference?

Oncocyte Corporation will participate in the Needham Virtual Cancer Diagnostics 1x1 Conference on August 18, 2020.

What is DetermaRx by Oncocyte Corporation?

DetermaRx is a treatment stratification test that identifies early-stage lung cancer patients at high risk for recurrence after surgery.

What does DetermaIO do?

DetermaIO is a gene expression test designed to identify patients likely to respond to checkpoint immunotherapies.

What is Oncocyte Corporation's stock symbol?

The stock symbol for Oncocyte Corporation is OCX.